| DC11313 |
NSC 146109 (hydrochloride)
Featured
|
NSC 146109 is an activator of the tumor suppressor p53 that increases expression of p53 and the p53 target DR5 in wild-type and p53-knockout HCT116 colon adenocarcinoma cells. |
|
| DC12509 |
NSC 146268 |
NSC 146268 (NSC146268, 6-Aza-2-thiouridine) is a novel small molecule inhibitor of CD151, inhibits proliferation of metastatic triple negative breast cancer cell lines (MDA-MB 231 and MDA-MB 468, IC50 of 6.0 and 6.2 ug/mL). |
|
| DC20918 |
NSC 15765 |
NSC 15765 (Compound C5, DNA2 inhibitor C5) is an effective, selective and competitive inhibitor of DNA2 nuclease with IC50 of 20 uM. |
|
| DC10695 |
NSC 191412
Featured
|
NSC 191412 is a bioactive compound. |
|
| DC21277 |
NSC 19630 |
NSC 19630 (MIRA-1) is a potent, selective Werner syndrome helicase (WRN helicase) with IC50 of 20 uM. |
|
| DC7963 |
NSC-23766 free base
Featured
|
NSC 23766 is a specific inhibitor of the binding and activation of RAC GTPase with IC50 of ~50 μM; does not inhibit the closely related targets, Cdc42 or RhoA. |
|
| DC8725 |
NSC 23766
Featured
|
NSC 23766 is a specific inhibitor of the binding and activation of Rac GTPase. |
|
| DC23598 |
NSC 23925 |
NSC 23925 is a small molecule compound that reverses multiple drug resistance (MDR) in human cancer cell lines, reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR. |
|
| DC23572 |
NSC 23925B |
NSC 23925B is a small molecule agent that reverses MDR in cancer cells, reverses MDR in several drug-resistant cell lines expressing Pgp. |
|
| DC10603 |
NSC 247030(SU5201)
Featured
|
NSC 247030 is a bioactive chemical. |
|
| DC21009 |
NSC 306711 |
NSC 306711 (Ferristatin, NSC306711) is a small-molecule iron transport inhibitor that promotes degradation of the transferrin receptor independent of clathrin and dynamin, is sensitive to the cholesterol-depleting agents filipin and nystatin.. |
|
| DC21420 |
NSC 311068 |
NSC 311068 is a small molecule that directly tragets and inhibits STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo. |
|
| DC10748 |
NSC31205
Featured
|
NSC 31205 is a PIM2/1 inhibitor. |
|
| DC21421 |
NSC 368262 |
NSC 368262 is a selective STAT3 inhibitor that alkylates Cys468 in Stat3, blocks the DNA-binding activity of phosphorylated Stat3 homodimers with IC50 of 10-50 uM, without inhibiting the DNA-binding of phosphorylated Stat1 homodimers. |
|
| DC21422 |
NSC 370284
Featured
|
NSC 370284 is a small molecule that directly binds to and inhibits STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo. |
|
| DC7215 |
NSC 405020
Featured
|
NSC 405020 is a noncatalytic inhibitor of MT1-MMP, directly interacts with PEX domain of MT1-MMP, affects PEX homodimerization but not catalytic activity of MT1-MMP. |
|
| DC10599 |
NSC 409012
Featured
|
NSC 409012 is a bioactive chemical. |
|
| DC21423 |
NSC 45576 |
NSC 45576 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 1.7 uM. |
|
| DC10703 |
NSC 6038
Featured
|
NSC 6038 is a bioactive compound. |
|
| DC20480 |
NSC 625987
Featured
|
NSC 625987 is a potent, selective CDK4 inhibitor with IC50 of 0.2 uM, displays >500-fold selectivity over CDK2 (IC50 >100 uM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E). . |
|
| DC23790 |
NSC 630668 |
NSC 630668 is a Hsc70 inhibitor that inhibits the endogenous and DnaJ-stimulated ATPase activity of hsc70. |
|
| DC23024 |
N-65828
Featured
|
NCI-65828 (designated as N 65828，NSC-65828) is a small-molecule inhibitor targeting angiogenin (ANG), a protein critical for angiogenesis and cellular proliferation. Its therapeutic potential stems from selective suppression of ANG's ribonucleolytic function, a biochemical activity essential for mediating downstream biological effects. By disrupting ANG's enzymatic capacity to cleave RNA substrates, NCI-65828 attenuates the protein's pro-angiogenic signaling pathways.
Preclinical evaluations highlight its multifaceted antitumor properties. In vitro studies using diverse cancer cell models—including bladder carcinoma (T24; IC₅₀ = 1.3 ± 0.5 μM), cervical adenocarcinoma (HeLa; IC₅₀ = 1.9 ± 0.4 μM), and urothelial carcinoma (UROtsa; IC₅₀ = 3.2 ± 0.8 μM)—demonstrate dose-dependent antiproliferative effects, with potency variations reflecting tissue-specific sensitivity. Parallel experiments in human umbilical vein endothelial cells (HUVECs) reveal significant inhibition of capillary-like tube formation, confirming its antiangiogenic efficacy in disrupting endothelial morphogenesis.
Notably, in vivo investigations using transgenic murine models demonstrate that NCI-65828 effectively suppresses the development of prostatic intraepithelial neoplasia (PIN) lesions. Mechanistic analysis indicates this activity arises from direct enzymatic inhibition rather than interference with ANG's intracellular trafficking, as nuclear translocation remains unaffected—a distinguishing feature that differentiates it from other ANG-targeted agents. This selective mode of action positions NCI-65828 as a precision tool for studying ANG-dependent pathologies.
|
|
| DC23822 |
NSC 658497 |
NSC 658497 is a small molecule inhibitor of Ras GEF, SOS1, binds to SOS1 with Kd of 7 uM but no H-Ras, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity. |
|
| DC21683 |
NSC 663284
Featured
|
NSC 663284 (SPS8I1;DA3003-1) is a potent inhibitor of the dual specificity protein phosphatase Cdc25 with Ki of 9/95//89 nM for Cdc25A/Cdc25B2/Cdc25C, displays 20- and 450-fold more selective over VHR or PTP1B phosphatases. |
|
| DC11327 |
NSC 668036 |
NSC 668036 is an inhibitor of the Dishevelled (Dvl) protein PDZ domain (Kd = 240 μM for mouse Dvl1 PDZ domain). |
|
| DC7879 |
NSC 66811 |
NSC 66811 is a potent MDM2 inhibitor (Ki = 120 nM). |
|
| DC23296 |
NSC 745887 |
NSC 745887 is a small molecule that effectively inhibits the proliferation of various cancers by trapping DNA-topoisomerase cleavage, shows anticancer effects against human GBM cells via suppressing DcR3-associated signaling pathways. |
|
| DC10697 |
NSC 80538
Featured
|
NSC 80538 is a bioactive compound. |
|
| DC22794 |
NSC112200
Featured
|
NSC112200 is a chemical inhibitor of the EZH2 deubiquitinase ZRANB1 (at 10 uM), destabilizes EZH2, promotes proteasomal degradation of EZH2 and inhibits the viability of TNBC cells. |
|
| DC9945 |
NSC-12 |
NSC12 is a PTX3-derived anti-FGF small molecule, inhibits FGF-dependent tumor growth, angiogenesis, and metastases,acts as a small-molecule FGF trap in cancer therapy. |
|
